Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 31-Mar-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 31-Mar-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg.